A lesson for cancer research: Placental microarray gene analysis in preeclampsia

Oncotarget

Volumn 3, Issue 8, 2012, Pages 759-773

  Louwen, Frank ^a   Muschol Steinmetz, Cornelia ^a   Reinhard, Joscha ^a   Reitter, Anke ^a   Yuan, Juping ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Angiogenesis; Cancer cells; Immune tolerance; Invasion; Preeclampsia

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; BINDING PROTEIN; ENDOGLIN; INHIBIN A; INTERLEUKIN 27; MESSENGER RNA; PLACENTAL GROWTH FACTOR; PROTEIN BCL 6; PROTEIN P28; SIGLEC 6; SORAFENIB; SUNITINIB; TRC 105; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1;

APOPTOSIS; BCL6 GENE; BODY MASS; CANCER INVASION; CANCER RESEARCH; CARCINOGENESIS; CELL MOTILITY; CELL SURVIVAL; DRUG SAFETY; ENDOGLIN GENE; EPSTEIN BARR INDUCED 13 GENE; FMS LIKE TYROSINE KINASE 1 GENE; GENE; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE IDENTIFICATION; GENE OVEREXPRESSION; GESTATIONAL AGE; HUMAN; HYPERTENSION; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; INHIBIN A GENE; LEPTIN GENE; LIGAND BINDING; MALIGNANT NEOPLASTIC DISEASE; MATERNAL AGE; MICROARRAY ANALYSIS; NONHUMAN; PATHOGENESIS; PREECLAMPSIA; PROTEINURIA; REVIEW; SIGLEC 6 GENE; TUMOR IMMUNITY; TUMOR VASCULARIZATION;

EID: 84868621849     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.595     Document Type: Review

References (137)

1. Ferretti C, Bruni L, Dangles-Marie V, Pecking AP, Bellet D. Molecular circuits shared by placental and cancer cells, and their implications in the proliferative, invasive and migratory capacities of trophoblasts. Hum Reprod Update 2007, 13: 121-141.
2. Boyd PA, Brown RA, Stewart WJ. Quantitative structural differences within the normal term hum;an placenta: a pilot study. Placenta 1980, 1: 337-344.
3. Loke YW, King A, Burrows TD. Decidua in human implantation. Hum Reprod 1995, 10 SUPPL 2: 14-21.
4. Holtan SG, Creedon DJ, Haluska P, Markovic SN. Cancer and pregnancy: parallels in growth, invasion, and immune modulation and implications for cancer therapeutic agents. Mayo Clin Proc 2009, 84: 985-1000.
5. Strickland S, Richards WG. Invasion of the trophoblasts. Cell 1992, 71: 355-357.
6. Soundararajan R, Rao AJ. Trophoblast 'pseudo-tumorigenesis': significance and contributory factors. Reprod Biol Endocrinol 2004, 2: 15.
7. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet 2005, 365: 785-799.
8. Redman CW, Sargent IL. Placental stress and pre-eclampsia: a revised view. Placenta 2009, 30 SUPPL A: S38-S42.
9. Grill S, Rusterholz C, Zanetti-Dallenbach R, Tercanli S, Holzgreve W, Hahn S et al. Potential markers of preeclampsia-a review. Reprod Biol Endocrinol 2009, 7: 70.
10. Sattar N, Greer IA. Pregnancy complications and maternal cardiovascular risk: opportunities for intervention and screening? BMJ 2002, 325: 157-160.
11. Roberts JM, Hubel CA. The two stage model of preeclampsia: variations on the theme. Placenta 2009, 30 SUPPL A: S32-S37.
12. Parham P. MHC class I molecules and KIRs in human history, health and survival. Nat Rev Immunol 2005, 5: 201-214.
13. Moffett A, Loke C. Immunology of placentation in eutherian mammals. Nat Rev Immunol 2006, 6: 584-594.
14. McMaster MT, Zhou Y, Fisher SJ. Abnormal placentation and the syndrome of preeclampsia. Semin Nephrol 2004, 24: 540-547.
15. Li H, Gu B, Zhang Y, Lewis DF, Wang Y. Hypoxia-induced increase in soluble Flt-1 production correlates with enhanced oxidative stress in trophoblast cells from the human placenta. Placenta 2005, 26: 210-217.
16. Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science 2005, 308: 1592-1594.
17. Roberts JM, Cooper DW. Pathogenesis and genetics of pre-eclampsia. Lancet 2001, 357: 53-56.
18. Brosens IA, Robertson WB, Dixon HG. The role of the spiral arteries in the pathogenesis of preeclampsia. Obstet Gynecol Annu 1972, 1: 177-191.
19. Gerretsen G, Huisjes HJ, Elema JD. Morphological changes of the spiral arteries in the placental bed in relation to pre-eclampsia and fetal growth retardation. Br J Obstet Gynaecol 1981, 88: 876-881.
20. Moodley J, Ramsaroop R. Placental bed morphology in black women with eclampsia. S Afr Med J 1989, 75: 376-378.
21. Egbor M, Ansari T, Morris N, Green CJ, Sibbons PD. Morphometric placental villous and vascular abnormalities in early-and late-onset pre-eclampsia with and without fetal growth restriction. BJOG 2006, 113: 580-589.
22. Schadt EE, Zhang B, Zhu J. Advances in systems biology are enhancing our understanding of disease and moving us closer to novel disease treatments. Genetica 2009, 136: 259-269.
23. Founds SA, Conley YP, Lyons-Weiler JF, Jeyabalan A, Hogge WA, Conrad KP. Altered global gene expression in first trimester placentas of women destined to develop preeclampsia. Placenta 2009, 30: 15-24.
24. Lapaire O, Grill S, Lalevee S, Kolla V, Hosli I, Hahn S. Microarray screening for novel preeclampsia biomarker candidates. Fetal Diagn Ther 2012, 31: 147-153.
25. Jarvenpaa J, Vuoristo JT, Savolainen ER, Ukkola O, Vaskivuo T, Ryynanen M. Altered expression of angiogenesis-related placental genes in pre-eclampsia associated with intrauterine growth restriction. Gynecol Endocrinol 2007, 23: 351-355.
26. Centlow M, Carninci P, Nemeth K, Mezey E, Brownstein M, Hansson SR. Placental expression profiling in preeclampsia: local overproduction of hemoglobin may drive pathological changes. Fertil Steril 2008, 90: 1834-1843.
27. Enquobahrie DA, Meller M, Rice K, Psaty BM, Siscovick DS, Williams MA. Differential placental gene expression in preeclampsia. Am J Obstet Gynecol 2008, 199: 566-11.
28. Winn VD, Gormley M, Paquet AC, Kjaer-Sorensen K, Kramer A, Rumer KK et al. Severe preeclampsia-related changes in gene expression at the maternal-fetal interface include sialic acid-binding immunoglobulin-like lectin-6 and pappalysin-2. Endocrinology 2009, 150: 452-462.
29. Sitras V, Paulssen RH, Gronaas H, Leirvik J, Hanssen TA, Vartun A et al. Differential placental gene expression in severe preeclampsia. Placenta 2009, 30: 424-433.
30. Lee GS, Joe YS, Kim SJ, Shin JC. Cytokine-related genes and oxidation-related genes detected in preeclamptic placentas. Arch Gynecol Obstet 2010, 282: 363-369.
31. Varkonyi T, Nagy B, Fule T, Tarca AL, Karaszi K, Schonleber J et al. Microarray profiling reveals that placental transcriptomes of early-onset HELLP syndrome and preeclampsia are similar. Placenta 2011, 32 SUPPL: S21-S29.
32. Tsai S, Hardison NE, James AH, Motsinger-Reif AA, Bischoff SR, Thames BH et al. Transcriptional profiling of human placentas from pregnancies complicated by preeclampsia reveals disregulation of sialic acid acetylesterase and immune signalling pathways. Placenta 2011, 32: 175-182.
33. Junus K, Centlow M, Wikstrom AK, Larsson I, Hansson SR, Olovsson M. Gene expression profiling of placentae from women with early-and late-onset pre-eclampsia: down-regulation of the angiogenesis-related genes ACVRL1 and EGFL7 in early-onset disease. Mol Hum Reprod 2012, 18: 146-155.
34. Toft JH, Lian IA, Tarca AL, Erez O, Espinoza J, Eide IP et al. Whole-genome microarray and targeted analysis of angiogenesis-regulating gene expression (ENG, FLT1, VEGF, PlGF) in placentas from pre-eclamptic and small-for-gestational-age pregnancies. J Matern Fetal Neonatal Med 2008, 21: 267-273.
35. Chang SD, Chao AS, Peng HH, Chang YL, Wang CN, Cheng PJ et al. Analyses of placental gene expression in pregnancy-related hypertensive disorders. Taiwan J Obstet Gynecol 2011, 50: 283-291.
36. Kang JH, Song H, Yoon JA, Park DY, Kim SH, Lee KJ et al. Preeclampsia leads to dysregulation of various signaling pathways in placenta. J Hypertens 2011, 29: 928-936.
37. Nishizawa H, Ota S, Suzuki M, Kato T, Sekiya T, Kurahashi H et al. Comparative gene expression profiling of placentas from patients with severe pre-eclampsia and unexplained fetal growth restriction. Reprod Biol Endocrinol 2011, 9: 107.
38. Meng T, Chen H, Sun M, Wang H, Zhao G, Wang X. Identification of differential gene expression profiles in placentas from preeclamptic pregnancies versus normal pregnancies by DNA microarrays. OMICS 2012, 16: 301-311.
39. Mayor-Lynn K, Toloubeydokhti T, Cruz AC, Chegini N. Expression profile of microRNAs and mRNAs in human placentas from pregnancies complicated by preeclampsia and preterm labor. Reprod Sci 2011, 18: 46-56.
40. Farina A, Zucchini C, De SP, Morano D, Sekizawa A, Purwosunu Y et al. Gene expression in chorionic villous samples at 11 weeks of gestation in women who develop pre-eclampsia later in pregnancy: implications for screening. Prenat Diagn 2011, 31: 181-185.
41. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006, 355: 992-1005.
42. Salahuddin S, Lee Y, Vadnais M, Sachs BP, Karumanchi SA, Lim KH. Diagnostic utility of soluble fms-like tyrosine kinase 1 and soluble endoglin in hypertensive diseases of pregnancy. Am J Obstet Gynecol 2007, 197: 28-6.
43. Nevo O, Soleymanlou N, Wu Y, Xu J, Kingdom J, Many A et al. Increased expression of sFlt-1 in in vivo and in vitro models of human placental hypoxia is mediated by HIF-1. Am J Physiol Regul Integr Comp Physiol 2006, 291: R1085-R1093.
44. Muttukrishna S, Swer M, Suri S, Jamil A, Calleja-Agius J, Gangooly S et al. Soluble Flt-1 and PlGF: new markers of early pregnancy loss? PLoS One 2011, 6: e18041.
45. Soleymanlou N, Jurisica I, Nevo O, Ietta F, Zhang X, Zamudio S et al. Molecular evidence of placental hypoxia in preeclampsia. J Clin Endocrinol Metab 2005, 90: 4299-4308.
46. Rajakumar A, Brandon HM, Daftary A, Ness R, Conrad KP. Evidence for the functional activity of hypoxia-inducible transcription factors overexpressed in preeclamptic placentae. Placenta 2004, 25: 763-769.
47. Kendall RL, Wang G, Thomas KA. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem Biophys Res Commun 1996, 226: 324-328.
48. Kendall RL, Thomas KA. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci U S A 1993, 90: 10705-10709.
49. Kondo K, Hiratsuka S, Subbalakshmi E, Matsushime H, Shibuya M. Genomic organization of the flt-1 gene encoding for vascular endothelial growth factor (VEGF) receptor-1 suggests an intimate evolutionary relationship between the 7-Ig and the 5-Ig tyrosine kinase receptors. Gene 1998, 208: 297-305.
50. He Y, Smith SK, Day KA, Clark DE, Licence DR, Charnock-Jones DS. Alternative splicing of vascular endothelial growth factor (VEGF)-R1 (FLT-1) pre-mRNA is important for the regulation of VEGF activity. Mol Endocrinol 1999, 13: 537-545.
51. Helske S, Vuorela P, Carpen O, Hornig C, Weich H, Halmesmaki E. Expression of vascular endothelial growth factor receptors 1, 2 and 3 in placentas from normal and complicated pregnancies. Mol Hum Reprod 2001, 7: 205-210.
52. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003, 111: 649-658.
53. Levine RJ, Qian C, Leshane ES, Yu KF, England LJ, Schisterman EF et al. Two-stage elevation of cell-free fetal DNA in maternal sera before onset of preeclampsia. Am J Obstet Gynecol 2004, 190: 707-713.
54. Shibuya M. Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. Cell Struct Funct 2001, 26: 25-35.
55. Thadhani R, Kisner T, Hagmann H, Bossung V, Noack S, Schaarschmidt W et al. Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia. Circulation 2011, 124: 940-950.
56. Sheffer M, Simon AJ, Jacob-Hirsch J, Rechavi G, Domany E, Givol D et al. Genome-wide analysis discloses reversal of the hypoxia-induced changes of gene expression in colon cancer cells by zinc SUPPLementation. Oncotarget 2011, 2: 1191-1202.
57. Michieli P. Hypoxia, angiogenesis and cancer therapy: to breathe or not to breathe? Cell Cycle 2009, 8: 3291-3296.
58. Demidenko ZN, Blagosklonny MV. The purpose of the HIF-1/PHD feedback loop: to limit mTOR-induced HIF-1alpha. Cell Cycle 2011, 10: 1557-1562.
59. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86: 353-364.
60. Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, Comoglio PM. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 2003, 3: 347-361.
61. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350: 2335-2342.
62. Cervello M, Bachvarov D, Lampiasi N, Cusimano A, Azzolina A, McCubrey JA et al. Molecular mechanisms of sorafenib action in liver cancer cells. Cell Cycle 2012, 11.
63. Shibuya M. Involvement of Flt-1 (VEGF receptor-1) in cancer and preeclampsia. Proc Jpn Acad Ser B Phys Biol Sci 2011, 87: 167-178.
64. Chaudhary A, St CB. Selective blockade of tumor angiogenesis. Cell Cycle 2012, 11: 2253-2259.
65. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 2003, 425: 577-584.
66. Zhang YE. Non-Smad pathways in TGF-beta signaling. Cell Res 2009, 19: 128-139.
67. Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim YM et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006, 12: 642-649.
68. Toporsian M, Gros R, Kabir MG, Vera S, Govindaraju K, Eidelman DH et al. A role for endoglin in coupling eNOS activity and regulating vascular tone revealed in hereditary hemorrhagic telangiectasia. Circ Res 2005, 96: 684-692.
69. Bernabeu C, Conley BA, Vary CP. Novel biochemical pathways of endoglin in vascular cell physiology. J Cell Biochem 2007, 102: 1375-1388.
70. Guo B, Slevin M, Li C, Parameshwar S, Liu D, Kumar P et al. CD105 inhibits transforming growth factor-beta-Smad3 signalling. Anticancer Res 2004, 24: 1337-1345.
71. Nassiri F, Cusimano MD, Scheithauer BW, Rotondo F, Fazio A, Yousef GM et al. Endoglin (CD105): a review of its role in angiogenesis and tumor diagnosis, progression and therapy. Anticancer Res 2011, 31: 2283-2290.
72. Fonsatti E, Nicolay HJ, Altomonte M, Covre A, Maio M. Targeting cancer vasculature via endoglin/CD105: a novel antibody-based diagnostic and therapeutic strategy in solid tumours. Cardiovasc Res 2010, 86: 12-19.
73. Lakshman M, Huang X, Ananthanarayanan V, Jovanovic B, Liu Y, Craft CS et al. Endoglin suppresses human prostate cancer metastasis. Clin Exp Metastasis 2011, 28: 39-53.
74. Tsujie M, Tsujie T, Toi H, Uneda S, Shiozaki K, Tsai H et al. Anti-tumor activity of an anti-endoglin monoclonal antibody is enhanced in immunocompetent mice. Int J Cancer 2008, 122: 2266-2273.
75. Uneda S, Toi H, Tsujie T, Tsujie M, Harada N, Tsai H et al. Anti-endoglin monoclonal antibodies are effective for suppressing metastasis and the primary tumors by targeting tumor vasculature. Int J Cancer 2009, 125: 1446-1453.
76. Rosen LS, Hurwitz HI, Wong MK, Goldman J, Mendelson DS, Figg WD et al. A Phase 1 First-in-Human Study of TRC105 (Anti-Endoglin Antibody) in Patients with Advanced Cancer. Clin Cancer Res 2012.
77. Gu Y, Lewis DF, Wang Y. Placental productions and expressions of soluble endoglin, soluble fms-like tyrosine kinase receptor-1, and placental growth factor in normal and preeclamptic pregnancies. J Clin Endocrinol Metab 2008, 93: 260-266.
78. Taylor RN, Grimwood J, Taylor RS, McMaster MT, Fisher SJ, North RA. Longitudinal serum concentrations of placental growth factor: evidence for abnormal placental angiogenesis in pathologic pregnancies. Am J Obstet Gynecol 2003, 188: 177-182.
79. Tidwell SC, Ho HN, Chiu WH, Torry RJ, Torry DS. Low maternal serum levels of placenta growth factor as an antecedent of clinical preeclampsia. Am J Obstet Gynecol 2001, 184: 1267-1272.
80. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011, 144: 646-674.
81. Oliveras-Ferraros C, Cufi S, Vazquez-Martin A, Menendez OJ, Bosch-Barrera J, Martin-Castillo B et al. Metformin rescues cell surface major histocompatibility complex class I (MHC-I) deficiency caused by oncogenic transformation. Cell Cycle 2012, 11.
82. Varki A, Angata T. Siglecs-the major subfamily of I-type lectins. Glycobiology 2006, 16: 1R-27R.
83. Cao H, Crocker PR. Evolution of CD33-related siglecs: regulating host immune functions and escaping pathogen exploitation? Immunology 2011, 132: 18-26.
84. Crocker PR, Varki A. Siglecs in the immune system. Immunology 2001, 103: 137-145.
85. Takei Y, Sasaki S, Fujiwara T, Takahashi E, Muto T, Nakamura Y. Molecular cloning of a novel gene similar to myeloid antigen CD33 and its specific expression in placenta. Cytogenet Cell Genet 1997, 78: 295-300.
86. Patel N, Brinkman-Van der Linden EC, Altmann SW, Gish K, Balasubramanian S, Timans JC et al. OB-BP1/ Siglec-6. a leptin-and sialic acid-binding protein of the immunoglobulin superfamily. J Biol Chem 1999, 274: 22729-22738.
87. Ravetch JV, Lanier LL. Immune inhibitory receptors. Science 2000, 290: 84-89.
88. Brinkman-Van der Linden EC, Hurtado-Ziola N, Hayakawa T, Wiggleton L, Benirschke K, Varki A et al. Human-specific expression of Siglec-6 in the placenta. Glycobiology 2007, 17: 922-931.
89. Lam KK, Chiu PC, Lee CL, Pang RT, Leung CO, Koistinen H et al. Glycodelin-A protein interacts with Siglec-6 protein to suppress trophoblast invasiveness by down-regulating extracellular signal-regulated kinase (ERK)/c-Jun signaling pathway. J Biol Chem 2011, 286: 37118-37127.
90. Chez RA. Nonhuman primate models of toxemia of pregnancy. Perspect Nephrol Hypertens 1976, 5: 421-424.
91. Chng WJ, Remstein ED, Fonseca R, Bergsagel PL, Vrana JA, Kurtin PJ et al. Gene expression profiling of pulmonary mucosa-associated lymphoid tissue lymphoma identifies new biologic insights with potential diagnostic and therapeutic applications. Blood 2009, 113: 635-645.
92. Devergne O, Hummel M, Koeppen H, Le Beau MM, Nathanson EC, Kieff E et al. A novel interleukin-12 p40-related protein induced by latent Epstein-Barr virus infection in B lymphocytes. J Virol 1996, 70: 1143-1153.
93. Devergne O, Coulomb-L'Hermine A, Capel F, Moussa M, Capron F. Expression of Epstein-Barr virus-induced gene 3, an interleukin-12 p40-related molecule, throughout human pregnancy: involvement of syncytiotrophoblasts and extravillous trophoblasts. Am J Pathol 2001, 159: 1763-1776.
94. Pflanz S, Timans JC, Cheung J, Rosales R, Kanzler H, Gilbert J et al. IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4(+) T cells. Immunity 2002, 16: 779-790.
95. Coulomb-L'Hermine A, Larousserie F, Pflanz S, Bardel E, Kastelein RA, Devergne O. Expression of interleukin-27 by human trophoblast cells. Placenta 2007, 28: 1133-1140.
96. Larousserie F, Bardel E, Pflanz S, Arnulf B, Lome-Maldonado C, Hermine O et al. Analysis of interleukin-27 (EBI3/p28) expression in Epstein-Barr virus-and human T-cell leukemia virus type 1-associated lymphomas: heterogeneous expression of EBI3 subunit by tumoral cells. Am J Pathol 2005, 166: 1217-1228.
97. Niedobitek G, Pazolt D, Teichmann M, Devergne O. Frequent expression of the Epstein-Barr virus (EBV)-induced gene, EBI3, an IL-12 p40-related cytokine, in Hodgkin and Reed-Sternberg cells. J Pathol 2002, 198: 310-316.
98. Nishino R, Takano A, Oshita H, Ishikawa N, Akiyama H, Ito H et al. Identification of Epstein-Barr virus-induced gene 3 as a novel serum and tissue biomarker and a therapeutic target for lung cancer. Clin Cancer Res 2011, 17: 6272-6286.
99. Knofler M, Pollheimer J. IFPA Award in Placentology lecture: molecular regulation of human trophoblast invasion. Placenta 2012, 33 SUPPL: S55-S62.
100. Pang ZJ, Xing FQ. Expression profile of trophoblast invasion-associated genes in the pre-eclamptic placenta. Br J Biomed Sci 2003, 60: 97-101.
101. Overall CM, Kleifeld O. Tumour microenvironment-opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer 2006, 6: 227-239.
102. Sharp AN, Heazell AE, Crocker IP, Mor G. Placental apoptosis in health and disease. Am J Reprod Immunol 2010, 64: 159-169.
103. Ishihara N, Matsuo H, Murakoshi H, Laoag-Fernandez JB, Samoto T, Maruo T. Increased apoptosis in the syncytiotrophoblast in human term placentas complicated by either preeclampsia or intrauterine growth retardation. Am J Obstet Gynecol 2002, 186: 158-166.
104. DiFederico E, Genbacev O, Fisher SJ. Preeclampsia is associated with widespread apoptosis of placental cytotrophoblasts within the uterine wall. Am J Pathol 1999, 155: 293-301.
105. Allaire AD, Ballenger KA, Wells SR, McMahon MJ, Lessey BA. Placental apoptosis in preeclampsia. Obstet Gynecol 2000, 96: 271-276.
106. Heazell AE, Buttle HR, Baker PN, Crocker IP. Altered expression of regulators of caspase activity within trophoblast of normal pregnancies and pregnancies complicated by preeclampsia. Reprod Sci 2008, 15: 1034-1043.
107. Han JY, Kim YS, Cho GJ, Roh GS, Kim HJ, Choi WJ et al. Altered gene expression of caspase-10, death receptor-3 and IGFBP-3 in preeclamptic placentas. Mol Cells 2006, 22: 168-174.
108. Papucci L, Schiavone N, Witort E, Donnini M, Lapucci A, Tempestini A et al. Coenzyme q10 prevents apoptosis by inhibiting mitochondrial depolarization independently of its free radical scavenging property. J Biol Chem 2003, 278: 28220-28228.
109. Basso K, Dalla-Favera R. BCL6: master regulator of the germinal center reaction and key oncogene in B cell lymphomagenesis. Adv Immunol 2010, 105: 193-210.
110. Phan RT, Dalla-Favera R. The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells. Nature 2004, 432: 635-639.
111. Ranuncolo SM, Polo JM, Dierov J, Singer M, Kuo T, Greally J et al. Bcl-6 mediates the germinal center B cell phenotype and lymphomagenesis through transcriptional repression of the DNA-damage sensor ATR. Nat Immunol 2007, 8: 705-714.
112. Ranuncolo SM, Polo JM, Melnick A. BCL6 represses CHEK1 and suppresses DNA damage pathways in normal and malignant B-cells. Blood Cells Mol Dis 2008, 41: 95-99.
113. Phan RT, Saito M, Basso K, Niu H, Dalla-Favera R. BCL6 interacts with the transcription factor Miz-1 to suppress the cyclin-dependent kinase inhibitor p21 and cell cycle arrest in germinal center B cells. Nat Immunol 2005, 6: 1054-1060.
114. Basso K, Dalla-Favera R. Roles of BCL6 in normal and transformed germinal center B cells. Immunol Rev 2012, 247: 172-183.
115. Basso K, Saito M, Sumazin P, Margolin AA, Wang K, Lim WK et al. Integrated biochemical and computational approach identifies BCL6 direct target genes controlling multiple pathways in normal germinal center B cells. Blood 2010, 115: 975-984.
116. Hoegh AM, Borup R, Nielsen FC, Sorensen S, Hviid TV. Gene expression profiling of placentas affected by pre-eclampsia. J Biomed Biotechnol 2010, 2010: 787545.
117. de Kretser DM, Hedger MP, Loveland KL, Phillips DJ. Inhibins, activins and follistatin in reproduction. Hum Reprod Update 2002, 8: 529-541.
118. Muttukrishna S, Knight PG, Groome NP, Redman CW, Ledger WL. Activin A and inhibin A as possible endocrine markers for pre-eclampsia. Lancet 1997, 349: 1285-1288.
119. Hamasaki T, Masuzaki H, Miyamura T, Yoshimura S, Hamaguchi N, Ishimaru T. High concentrations of serum inhibin in pre-eclampsia. Int J Gynaecol Obstet 2000, 71: 7-11.
120. Florio P, Cobellis L, Luisi S, Ciarmela P, Severi FM, Bocchi C et al. Changes in inhibins and activin secretion in healthy and pathological pregnancies. Mol Cell Endocrinol 2001, 180: 123-130.
121. Muttukrishna S, Child TJ, Groome NP, Ledger WL. Source of circulating levels of inhibin A, pro alpha C-containing inhibins and activin A in early pregnancy. Hum Reprod 1997, 12: 1089-1093.
122. Shen Z, Cai LY, Suprapto IS, Shenoy P, Zhou X. Placental and maternal serum inhibin A in patients with preeclampsia and small-for-gestational-age. J Obstet Gynaecol Res 2011, 37: 1290-1296.
123. Bersinger NA, Groome N, Muttukrishna S. Pregnancy-associated and placental proteins in the placental tissue of normal pregnant women and patients with pre-eclampsia at term. Eur J Endocrinol 2002, 147: 785-793.
124. Reimer T, Koczan D, Gerber B, Richter D, Thiesen HJ, Friese K. Microarray analysis of differentially expressed genes in placental tissue of pre-eclampsia: up-regulation of obesity-related genes. Mol Hum Reprod 2002, 8: 674-680.
125. Herse F, Dechend R, Harsem NK, Wallukat G, Janke J, Qadri F et al. Dysregulation of the circulating and tissue-based renin-angiotensin system in preeclampsia. Hypertension 2007, 49: 604-611.
126. Nishizawa H, Pryor-Koishi K, Kato T, Kowa H, Kurahashi H, Udagawa Y. Microarray analysis of differentially expressed fetal genes in placental tissue derived from early and late onset severe pre-eclampsia. Placenta 2007, 28: 487-497.
127. Laivuori H, Gallaher MJ, Collura L, Crombleholme WR, Markovic N, Rajakumar A et al. Relationships between maternal plasma leptin, placental leptin mRNA and protein in normal pregnancy, pre-eclampsia and intrauterine growth restriction without pre-eclampsia. Mol Hum Reprod 2006, 12: 551-556.
128. Masuyama H, Segawa T, Sumida Y, Masumoto A, Inoue S, Akahori Y et al. Different profiles of circulating angiogenic factors and adipocytokines between early-and late-onset pre-eclampsia. BJOG 2010, 117: 314-320.
129. Lu D, Yang X, Wu Y, Wang H, Huang H, Dong M. Serum adiponectin, leptin and soluble leptin receptor in pre-eclampsia. Int J Gynaecol Obstet 2006, 95: 121-126.
130. Maymo JL, Perez AP, Gambino Y, Calvo JC, Sanchez-Margalet V, Varone CL. Review: Leptin gene expression in the placenta-regulation of a key hormone in trophoblast proliferation and survival. Placenta 2011, 32 SUPPL 2: S146-S153.
131. Schroeter MR, Leifheit M, Sudholt P, Heida NM, Dellas C, Rohm I et al. Leptin enhances the recruitment of endothelial progenitor cells into neointimal lesions after vascular injury by promoting integrin-mediated adhesion. Circ Res 2008, 103: 536-544.
132. Porter GA, Inglis KM, Wood LA, Veugelers PJ. Effect of obesity on presentation of breast cancer. Ann Surg Oncol 2006, 13: 327-332.
133. Loi S, Milne RL, Friedlander ML, McCredie MR, Giles GG, Hopper JL et al. Obesity and outcomes in premenopausal and postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev 2005, 14: 1686-1691.
134. McTiernan A. Obesity and cancer: the risks, science, and potential management strategies. Oncology (Williston Park) 2005, 19: 871-881.
135. Fontana L, Eagon JC, Trujillo ME, Scherer PE, Klein S. Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes 2007, 56: 1010-1013.
136. Iyengar P, Combs TP, Shah SJ, Gouon-Evans V, Pollard JW, Albanese C et al. Adipocyte-secreted factors synergistically promote mammary tumorigenesis through induction of anti-apoptotic transcriptional programs and proto-oncogene stabilization. Oncogene 2003, 22: 6408-6423.
137. Manabe Y, Toda S, Miyazaki K, Sugihara H. Mature adipocytes, but not preadipocytes, promote the growth of breast carcinoma cells in collagen gel matrix culture through cancer-stromal cell interactions. J Pathol 2003, 201: 221-228.